Ionis Pharmaceuticals (NASDAQ:IONS) Receives Outperform Rating from William Blair

William Blair restated their outperform rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS) in a report published on Friday morning,RTT News reports. William Blair also issued estimates for Ionis Pharmaceuticals’ FY2028 earnings at $2.07 EPS.

A number of other brokerages have also issued reports on IONS. JPMorgan Chase & Co. boosted their price target on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Royal Bank of Canada reissued an “outperform” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, September 26th. Piper Sandler cut their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Guggenheim lowered their price objective on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

Ionis Pharmaceuticals Trading Up 0.1 %

Shares of IONS opened at $35.63 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The firm has a market capitalization of $5.63 billion, a price-to-earnings ratio of -14.60 and a beta of 0.35. The company has a 50-day moving average of $37.38 and a 200 day moving average of $42.27. Ionis Pharmaceuticals has a 1-year low of $33.33 and a 1-year high of $54.44.

Insider Buying and Selling

In other news, CEO Brett P. Monia sold 6,630 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the transaction, the chief executive officer now directly owns 167,393 shares of the company’s stock, valued at $6,369,303.65. The trade was a 3.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Eric Swayze sold 1,194 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the sale, the executive vice president now directly owns 33,713 shares in the company, valued at $1,278,396.96. This trade represents a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,877 shares of company stock valued at $299,578 over the last 90 days. Insiders own 2.71% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in IONS. GAMMA Investing LLC increased its stake in shares of Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares in the last quarter. nVerses Capital LLC purchased a new stake in Ionis Pharmaceuticals during the 2nd quarter worth approximately $29,000. Itau Unibanco Holding S.A. acquired a new position in shares of Ionis Pharmaceuticals during the second quarter valued at approximately $37,000. Capital Performance Advisors LLP purchased a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $40,000. Finally, Prospera Private Wealth LLC acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter worth approximately $42,000. 93.86% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.